DBV Technologies (DBVT) Cash & Current Investments (2015 - 2026)
DBV Technologies (DBVT) posted Cash & Current Investments of $174.9 million for Q2 2026, down 23.69% sequentially from $229.2 million in Q1 2026, and up 69.47% YoY from $103.2 million in Q2 2025.
Analysis
DBV Technologies (DBVT) Cash & Current Investments (2015 - 2026) Analysis & Trends
DBV Technologies has reported Cash & Current Investments for 12 years, with the latest figure at $174.9 million in Q2 2026.
- Quarterly Cash & Current Investments rose 69.47% year-over-year to $174.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $174.9 million (up 69.47% YoY) and the FY2025 annual result came in at $194.2 million, up 498.35% from the prior year.
- Cash & Current Investments slipped to $174.9 million in Q2 2026 per DBVT's latest filing, from $229.2 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $248.0 million in Q2 2022 and troughed at $13.0 million in Q1 2025.
- A 5-year average of $135.1 million and a median of $145.3 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2025 and 2026: Cash & Current Investments sank 87.23% in 2025, then soared 1668.25% in 2026.
- Over 5 years, Cash & Current Investments stood at $209.2 million in 2022, then plunged by 32.42% to $141.4 million in 2023, then sank by 77.04% to $32.5 million in 2024, then surged by 498.35% to $194.2 million in 2025, then dropped by 9.94% to $174.9 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $174.9 million, $229.2 million, and $194.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | 174.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 174.90 Mn |
| Mar 31, 2026 | 229.20 Mn |
| Dec 31, 2025 | 194.20 Mn |
| Sep 30, 2025 | 69.84 Mn |
| Jun 30, 2025 | 103.21 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 32.46 Mn |
| Sep 30, 2024 | 46.44 Mn |
| Jun 30, 2024 | 66.21 Mn |
| Mar 31, 2024 | 101.53 Mn |
| Dec 31, 2023 | 141.37 Mn |
| Sep 30, 2023 | 149.14 Mn |
| Jun 30, 2023 | 173.96 Mn |
| Mar 31, 2023 | 192.29 Mn |
| Dec 31, 2022 | 209.19 Mn |
| Sep 30, 2022 | 212.67 Mn |
| Jun 30, 2022 | 247.97 Mn |
| Mar 31, 2022 | 74.11 Mn |
| Dec 31, 2021 | 77.30 Mn |
| Sep 30, 2021 | 98.20 Mn |